Skip to main content

Table 5 Univariate and multivariate analyses of OS

From: Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis

Characteristic Before PSM After PSM
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95%CI p HR 95%CI p HR 95% CI p HR 95% CI p
Age (years) ≤ 60 Reference   Reference   Reference   Reference  
>  60 1.186 1.128–1.248 < 0.001 1.203 1.143–1.267 < 0.001 1.228 1.101–1.371 < 0.001 1.150 1.030–1.284 0.013
Gender Female Reference     NI Reference     NI
Male 1.046 0.999–1.096 0.053     1.011 0.948–1.077 0.746    
Race Black Reference   Reference   Reference   Reference  
White 0.905 0.845–0.970 0.005 0.934 0.872–1.002 0.056 0.898 0.814–0.991 0.032 0.931 0.843–1.028 0.156
Others 0.890 0.804–0.986 0.026 0.920 0.830–1.020 0.113 0.875 0.755–1.013 0.074 0.948 0.818–1.099 0.477
Tumor site Head Reference   Reference   Reference   Reference  
Body 1.363 1.273–1.461 < 0.001 0.929 0.865–0.998 0.043 1.307 1.188–1.437 < 0.001 0.966 0.874–1.066 0.489
Tail 1.412 1.317–1.513 < 0.001 0.988 0.919–1.062 0.751 1.456 1.326–1.599 < 0.001 1.039 0.942–1.146 0.443
Pancreatic duct 1.458 1.336–1.590 < 0.001 0.995 0.910–1.089 0.921 1.483 1.314–1.674 < 0.001 1.019 0.899–1.156 0.769
Others 1.424 1.304–1.555 < 0.001 0.971 0.886–1.064 0.522 1.459 1.299–1.638 < 0.001 0.931 0.824–1.053 0.254
Tumor size (cm) ≤ 2 Reference   Reference   Reference   Reference  
2~4 1.429 1.310–1.559 < 0.001 1.159 1.034–1.300 0.011 1.392 1.238–1.564 < 0.001 1.215 1.033–1.430 0.019
> 4 2.162 1.980–2.361 < 0.001 1.407 1.252–1.581 < 0.001 2.127 1.888–2.397 < 0.001 1.459 1.236–1.722 < 0.001
Tumor grade Well Reference   Reference   Reference   Reference  
Moderate 1.116 1.028–1.212 0.009 1.233 1.135–1.339 < 0.001 1.030 0.923–1.148 0.599 1.204 1.078–1.345 0.001
Poor 1.601 1.476–1.736 < 0.001 1.584 1.459–1.719 < 0.001 1.412 1.267–1.573 < 0.001 1.446 1.295–1.615 < 0.001
Undifferentiated 1.697 1.416–2.034 < 0.001 1.357 1.131–1.628 0.001 1.633 1.320–2.019 < 0.001 1.377 1.111–1.707 0.004
T stage T0 Reference   Reference   Reference   Reference  
T1 0.200 0.139–0.287 < 0.001 0.334 0.231–0.483 < 0.001 0.250 0.164–0.380 < 0.001 0.374 0.242–0.577 < 0.001
T2 0.471 0.335–0.661 < 0.001 0.451 0.313–0.650 < 0.001 0.547 0.370–0.807 0.002 0.480 0.311–0.742 0.001
T3 0.288 0.205–0.404 < 0.001 0.444 0.309–0.638 < 0.001 0.351 0.238–0.517 < 0.001 0.483 0.313–0.743 0.001
T4 0.480 0.342–0.674 < 0.001 0.450 0.313–0.648 < 0.001 0.578 0.391–0.855 0.006 0.462 0.299–0.714 < 0.001
N stage N0 Reference   Reference   Reference   Reference  
N1 0.925 0.881–0.971 0.002 1.100 1.046–1.156 < 0.001 0.905 0.845–0.969 0.004 1.096 1.021–1.176 0.011
N2 0.591 0.544–0.641 < 0.001 1.396 1.268–1.537 < 0.001 0.575 0.511–0.647 < 0.001 1.408 1.226–1.616 < 0.001
Metastasis Absent Reference   Reference   Reference   Reference  
Present 2.874 2.739–3.015 < 0.001 1.702 1.608–1.802 < 0.001 2.911 2.723–3.112 < 0.001 1.719 1.589–1.859 < 0.001
Surgery Performed Reference   Reference   Reference   Reference  
Recommended, not performed 3.367 2.948–3.846 < 0.001 2.570 2.232–2.959 < 0.001 3.365 2.881–3.929 < 0.001 2.626 2.221–3.105 < 0.001
Not recommended 3.431 3.255–3.618 < 0.001 2.608 2.419–2.813 < 0.001 3.582 3.323–3.861 < 0.001 2.684 2.416–2.982 < 0.001
Radiotherapy No Reference   Reference   Reference   Reference  
Yes 0.369 0.341–0.399 < 0.001 0.887 0.813–0.969 0.008 0.369 0.330–0.412 < 0.001 0.860 0.759–0.974 0.017
Chemotherapy No Reference   Reference   Reference   Reference  
Yes 0.445 0.425–0.467 < 0.001 0.435 0.414–0.457 < 0.001 0.450 0.422–0.480 < 0.001 0.451 0.422–0.483 < 0.001
Prior cancer Without Reference   Reference   Reference   Reference  
With 1.030 0.925–1.147 0.587 1.014 0.910–1.130 0.796 0.993 0.889–1.108 0.894 1.018 0.912–1.136 0.754
  1. OS Overall survival, HR Hazard ratio